UBS Group’s Biocept, Inc. BIOC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-124
| Closed | -$155 | – | 10567 |
|
|
2023
Q3 | $155 | Buy |
+124
| New | +$149 | ﹤0.01% | 8777 |
|
|
2023
Q2 | – | Sell |
-147
| Closed | -$1.5K | – | 10324 |
|
|
2023
Q1 | $1.5K | Sell |
147
-127
| -46% | -$1.84K | ﹤0.01% | 8722 |
|
|
2022
Q4 | $4.36K | Sell |
274
-138
| -33% | -$3.04K | ﹤0.01% | 9348 |
|
|
2022
Q3 | $11K | Buy |
+412
| New | +$12.2K | ﹤0.01% | 8367 |
|
|
2022
Q2 | – | Sell |
-71
| Closed | -$5K | – | 11396 |
|
|
2022
Q1 | $5K | Buy |
+71
| New | +$5.58K | ﹤0.01% | 9217 |
|
|
2021
Q4 | – | Sell |
-66
| Closed | -$8K | – | 11022 |
|
|
2021
Q3 | $8K | Buy |
+66
| New | +$7.7K | ﹤0.01% | 8254 |
|
|
2020
Q3 | – | Sell |
-4
| Closed | -$1K | – | 8591 |
|
|
2020
Q2 | $1K | Sell |
4
-250
| -98% | -$35.9K | ﹤0.01% | 7838 |
|
|
2020
Q1 | $20K | Buy |
254
+152
| +149% | +$15.5K | ﹤0.01% | 6510 |
|
|
2019
Q4 | $9K | Buy |
+102
| New | +$17.6K | ﹤0.01% | 7361 |
|
|
2019
Q3 | – | Sell |
-27
| Closed | -$9K | – | 8370 |
|
|
2019
Q2 | $9K | Buy |
27
+12
| +80% | +$3.8K | ﹤0.01% | 7152 |
|
|
2019
Q1 | $5K | Buy |
+15
| New | +$6.08K | ﹤0.01% | 7202 |
|
|
2018
Q3 | – | Sell |
-4
| Closed | -$8K | – | 8374 |
|
|
2018
Q2 | $8K | Sell |
4
-7
| -64% | -$14.2K | ﹤0.01% | 7288 |
|
|
2018
Q1 | $28K | Buy |
11
+3
| +38% | +$11.3K | ﹤0.01% | 6161 |
|
|
2017
Q4 | $52K | Buy |
+8
| New | +$63.2K | ﹤0.01% | 5814 |
|
|
2017
Q2 | – | Hold |
0
| – | -$3K | – | 8091 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 7215 |
|
|
2016
Q4 | – | Hold |
0
| – | -$6K | – | 8134 |
|
|
2016
Q3 | – | Sell |
-1
| Closed | -$16.3K | – | 7080 |
|
|
2016
Q2 | $15K | Buy |
+1
| New | +$24.2K | ﹤0.01% | 6530 |
|
|
2016
Q1 | – | Hold |
0
| – | -$1K | – | 8350 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 8194 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6923 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 9550 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 9693 |
|
UBS Group's BIOC Position: Q4 2023 in Review
UBS Group sold out of Biocept, Inc. (BIOC) in Q4 2023, closing a stake of 124 shares — an estimated $155 sold.
UBS Group first reported a position in BIOC in Q2 2016 and held it in 15 quarters. The position peaked at $52K in Q4 2017. 0 funds tracked by Wall St. Rank hold BIOC as of Q4 2023.
- UBS Group reported no remaining Biocept, Inc. position as of Q4 2023 after selling out during the quarter.
- UBS Group sold 124 Biocept, Inc. shares in Q4 2023, an estimated $155.
- UBS Group first reported a position in Biocept, Inc. in Q2 2016 and held it in 15 quarters.
- UBS Group's Biocept, Inc. position peaked at $52K in Q4 2017.
- 0 funds tracked by Wall St. Rank held Biocept, Inc. as of Q4 2023.
Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.